Shelly Gunn has been named medical director of CombiMatrix Molecular Diagnostics, CMDX said this week.
Gunn currently serves as clinical assistant professor in the department of pathology at the University of Texas Health Science Center at San Antonio.
She holds a PhD in genetics from the UTHSCSA Graduate School of Biomedical Sciences, an MD from the UTHSCSA Medical School, and a BA and MA from TrinityUniversity.
John Tonkinson has been named vice president of business development at HistoRx, the company said last week.
Tonkinson previously served as director of business development at Epitome BioSystems. Prior to joining Epitome, he held sales and marketing management positions at Schleicher & Schuell BioScience.
Tonkinson holds a PhD, an MPhil, and an MA in biochemistry and molecular biophysics from Columbia University and a BSc in biochemistry from Philadelphia College of Pharmacy and Science.
Richard Eglen has joined PerkinElmer as vice president and general manager of discovery and research reagents for PE’s Life & Analytical Sciences unit, the company said last week.
He joins PerkinElmer from DiscoveRx, where he served as chief scientific officer and executive vice president for research and development.
Eglen has a PhD in molecular pharmacology from TrentUniversity in Nottingham, UK.
Guenter Jaensch and Kerry Frey have joined BioForce NanoSciences’ board of directors, the company said recently.
Jaensch is a former executive at Siemens, where he served as president of Siemens Communications, chairman & president of Siemens Corporate Research and Support, and chairman and CEO of Siemens Pacesetter. Since 1997, Jaensch has been a director of MRV Communications. He also serves as chairman of the board of Biophan Technologies.
Frey currently serves as BioForce’s chief operating officer.